1. Frost G: The latency period of mesothelioma among a cohort
of British asbestos workers (1978‑2005). Br J Cancer 109:
1965‑1973, 2013.
2. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and
Sorahan T: Global mesothelioma deaths reported to the World
Health Organization between 1994 and 2008. Bull World Health
Organ 89: 716‑724, 724A‑724C, 2011.
3. Murayama T, Takahashi K, Natori Y and Kurumatani N:
Estimation of future mortality from pleural malignant meso‑
thelioma in Japan based on an age‑cohort model. Am J Ind
Med 49: 1‑7, 2006.
4. Joshi TK and Gupta RK: Asbestos in developing countries:
Magnitude of risk and its practical implications. Int J Occup Med
Environ Health 17: 179‑185, 2004.
5. Yap TA, Aerts JG, Popat S and Fennell DA: Novel insights into
mesothelioma biology and implications for therapy. Nat Rev
Cancer 17: 475‑488, 2017.
6. Ponting CP, Oliver PL and Reik W: Evolution and functions of
long noncoding RNAs. Cell 136: 629‑641, 2009.
7. Mattick JS: The genetic signatures of noncoding RNAs. PLoS
Genet 5: e1000459, 2009.
8. Kapranov P, St Laurent G, Raz T, Ozsolak F, Reynolds CP,
Sorensen PH, Reaman G, Milos P, Arceci RJ, Thompson JF, et al:
The majority of total nuclear‑encoded non‑ribosomal RNA in a
human cell is ‘dark matter’ un‑annotated RNA. BMC Biol 8: 149,
2010.
9. Gibb EA, Brown CJ and Lam WL: The functional role of long
non‑coding RNA in human carcinomas. Mol Cancer 10: 38,
2011.
10. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM,
Kennett JY, Becker‑Santos DD, MacAulay CE, Lam S,
Brown CJ, et al: Human cancer long non‑coding RNA tran‑
scriptomes. PLoS One 6: e25915, 2011.
11. Brosnan CA and Voinnet O: The long and the short of noncoding
RNAs. Curr Opin Cell Biol 21: 416‑425, 2009.
12. Mercer TR, Dinger ME and Mattick JS: Long non‑coding RNAs:
Insights into functions. Nat Rev Genet 10: 155‑159, 2009.
13. Statello L, Guo CJ, Chen LL and Huarte M: Gene regulation by
long non‑coding RNAs and its biological functions. Nat Rev Mol
Cell Biol 22: 96‑118, 2021.
14. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D,
Huarte M, Zuk O, Carey BW, Cassady JP, et al: Chromatin
signature reveals over a thousand highly conserved large
non‑coding RNAs in mammals. Nature 458: 223‑227, 2009.
15. Costa FF: Non‑coding RNAs: Meet thy masters. BioEssays 32:
599‑608, 2010.
16. Huarte M and Rinn JL: Large non‑coding RNAs: Missing links
in cancer? Hum Mol Genet 19: R152‑R161, 2010.
17. Cui M, You L, Ren X, Zhao W, Liao Q and Zhao Y: Long
non‑coding RNA PVT1 and cancer. Biochem Biophys Res
Commun 471: 10‑14, 2016.
18. Wang D and Hu Y: Long Non‑coding RNA PVT1 Competitively
Binds MicroRNA‑424‑5p to Regulate CARM1 in Radiosensitivity
of Non‑Small‑Cell Lung Cancer. Mol Ther Nucleic Acids 16:
130‑140, 2019.
10
FUJII et al: PVT1 lncRNA EXPRESSION IN MESOTHELIOMA
19. Hu J, Han Q, Gu Y, Ma J, McGrath M, Qiao F, Chen B, Song C
and Ge Z: Circular RNA PVT1 expression and its roles in acute
lymphoblastic leukemia. Epigenomics 10: 723‑732, 2018.
20. Guo J, Hao C, Wang C and Li L: Long noncoding RNA PVT1
modulates hepatocellular carcinoma cell proliferation and
apoptosis by recruiting EZH2. Cancer Cell Int 18: 98, 2018.
21. Zhang R, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W
and Liu Y: Long Noncoding RNA Plasmacytoma Variant
Translocation 1 (PVT1) Promotes Colon Cancer Progression via
Endogenous Sponging miR‑26b. Med Sci Monit 24: 8685‑8692,
2018.
22. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J,
Mao JH, Yu M, Miller MA, Santos JL, et al: Amplification of
PVT1 contributes to the pathophysiology of ovarian and breast
cancer. Clin Cancer Res 13: 5745‑5755, 2007.
23. Yang Q, Yu Y, Sun Z and Pan Y: Long non‑coding RNA PVT1
promotes cell proliferation and invasion through regulating
miR‑133a in ovarian cancer. Biomed Pharmacother 106: 61‑67,
2018.
24. Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y,
Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, et al:
Identification of DAB2 and Intelectin‑1 as Novel Positive
Immunohistochemical Markers of Epithelioid Mesothelioma by
Transcriptome Microarray Analysis for Its Differentiation From
Pulmonary Adenocarcinoma. Am J Surg Pathol 41: 1045‑1052,
2017.
25. Barretina J, Caponigro G, Stransky N, Venkatesan K,
Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Erratum in:
Nature 492: 290, 2012.
26. Livak KJ and Schmittgen TD: Analysis of relative gene
expression data using real‑time quantitative PCR and the 2(‑Δ Δ
C(T)) Method. Methods 25: 402‑408, 2001.
27. Gebäck T, Schulz MM, Koumoutsakos P and Detmar M:
TScratch: A novel and simple software tool for automated
analysis of monolayer wound healing assays. Biotechniques 46:
265‑274, 2009.
28. Lamprecht MR, Sabatini DM and Carpenter AE: CellProfiler:
Free, versatile software for automated biological image analysis.
Biotechniques 42: 71‑75, 2007.
29. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F,
Merler E, Gennaro V, Romanelli A, Chellini E, Pascucci C, et al:
Survival of pleural malignant mesothelioma in Italy: A popu‑
lation‑based study. Int J Cancer 124: 201‑207, 2009.
30. Cao C, Tian D, Park J, Allan J, Pataky KA and Yan TD: A
systematic review and meta‑analysis of surgical treatments for
malignant pleural mesothelioma. Lung Cancer 83: 240‑245, 2014.
31. Bunch H: Gene regulation of mammalian long non‑coding RNA.
Mol Genet Genomics 293: 1‑15, 2018.
32. Chi Y, Wang D, Wang J, Yu W and Yang J: Long Non‑Coding
RNA in the Pathogenesis of Cancers. Cells 8: 1015, 2019.
33. Wright CM, Kirschner MB, Cheng YY, O'Byrne KJ,
Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van
Zandwijk N, et al: Long non coding RNAs (lncRNAs) are
dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS
One 8: e70940, 2013.
34. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY,
Rice DC, Tsao A and Wistuba II: Frequent coamplification and
cooperation between C‑MYC and PVT1 oncogenes promote
malignant pleural mesothelioma. J Thorac Oncol 9: 998‑1007,
2014.
35. Yang A, Wang H and Yang X: Long non‑coding RNA PVT1
indicates a poor prognosis of glioma and promotes cell
proliferation and invasion via target EZH2. Biosci Rep 37:
BSR20170871, 2017.
36. Fei BY, He X, Ma J, Zhang M and Chai R: FOXM1 is associated
with metastasis in colorectal cancer through induction of the
epithelial‑mesenchymal transition. Oncol Lett 14: 6553‑6561,
2017.
37. Shi C and Zhang Z: MicroRNA‑320 suppresses cervical cancer
cell viability, migration and invasion via directly targeting
FOXM1. Oncol Lett 14: 3809‑3816, 2017.
38. Zhang J, Chen XY, Huang KJ, Wu WD, Jiang T, Cao J,
Zhou LS, Qiu ZJ and Huang C: Expression of FOXM1 and the
EMT‑associated protein E‑cadherin in gastric cancer and its
clinical significance. Oncol Lett 12: 2445‑2450, 2016.
39. Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P,
Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, et al:
FOXM1 expression is significantly associated with chemo‑
therapy resistance and adverse prognosis in non‑serous epithelial
ovarian cancer patients. J Exp Clin Cancer Res 36: 63, 2017.
40. Zhang H, Zhong H, Li L, Ji W and Zhang X: Overexpressed
transcription factor FOXM1 contributes to the progression of
colorectal cancer. Mol Med Rep 13: 2696‑2700, 2016.
41. Zhang J, Niu Y and Huang C: Role of FOXM1 in the Progression
and Epithelial to Mesenchymal Transition of Gastrointestinal
Cancer. Recent Patents Anticancer Drug Discov 12: 247‑259,
2017.
42. Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, Guo YH, Shi J,
Gong XD, Zhu YL, Liu F, et al: Overexpression of FOXM1 is
associated with EMT and is a predictor of poor prognosis in
non‑small cell lung cancer. Oncol Rep 31: 2660‑2668, 2014.
43. Li M, Chi C, Zhou L, Chen Y and Tang X: Circular PVT1 regulates
cell proliferation and invasion via miR‑149‑5p/FOXM1 axis in
ovarian cancer. J Cancer 12: 611‑621, 2021.
44. Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C,
Ni SJ, Dong L, Yang Y, et al: A Positive Feedback Loop of
lncRNA‑PVT1 and FOXM1 Facilitates Gastric Cancer Growth
and Invasion. Clin Cancer Res 23: 2071‑2080, 2017.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
